# Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

> **NCT01390571** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 34 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** olaparib
- **DRUG:** temozolomide
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** diffusion-weighted magnetic resonance imaging
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01390571
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2017-06-20
- **Final completion:** 2017-06-20
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01390571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01390571, "Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01390571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*